PDLIM7 and nasopharyngeal carcinoma: This process is recapitulated by overexpression of EBV latent membrane protein 1 (LMP1) and LMP2A but blocked by treatment of GLI1/2 inhibitor GANT 58 or GANT 61, indicating that EBV drives NPC progression through LMP1- and LMP2A-mediated activation of HH signaling.